Zomarist

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

вилдаглиптин, метформин хидрохлорид

Available from:

Novartis Europharm Limited 

ATC code:

A10BD08

INN (International Name):

vildagliptin, metformin

Therapeutic group:

Лекарства, използвани при диабет

Therapeutic area:

Захарен диабет тип 2

Therapeutic indications:

Zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Product summary:

Revision: 23

Authorization status:

упълномощен

Authorization date:

2008-11-30

Patient Information leaflet

                                43
Б. ЛИСТОВКА
44
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
ZOMARIST 50 MG/850 MG ФИЛМИРАНИ ТАБЛЕТКИ
ZOMARIST 50 MG/1000 MG ФИЛМИРАНИ ТАБЛЕТКИ
vildagliptin/metformin hydrochloride
(вилдаглиптин/метформин хидрохлорид)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар,
фармацевт или
медицинска сестра.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите като Вашите.
-
Ако получите някакви нежелани
реакции, уведомете Вашия лекар,
фармацевт или
медицинска сестра. Това включва и
всички възможни нежелани реакции,
неописани в
тази листовка. Вижте точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява Zomarist и за какво се
използва
2.
Какво трябва да знаете, преди да
приемете Zomarist
3.
Как да приемате Zomarist
4.
Възможни нежелани реакции
5.
Как да съхранявате Zomarist
6.
Съдържание на опаковката и
допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА ZOMARIST И ЗА КАКВО СЕ
И
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Zomarist 50 mg/850 mg филмирани таблетки
Zomarist 50 mg/1000 mg филмирани таблетки
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Zomarist 50 mg/850 mg филмирани таблетки
Всяка филмирана таблетка съдържа 50 mg
вилдаглиптин (vildagliptin) и 850 mg метформин
хидрохлорид (metformin hydrochloride)
(еквивалентни на 660 mg метформин).
Zomarist 50 mg/1000 mg филмирани таблетки
Всяка филмирана таблетка съдържа 50 mg
вилдаглиптин (vildagliptin) и 1000 mg метформин
хидрохлорид (metformin hydrochloride)
(еквивалентни на 780 mg метформин).
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Филмиранa таблеткa
Zomarist 50 mg/850 mg филмирани таблетки
Жълта, елипсовидна филмирана таблетка
със скосени ръбове, с напечатани “NVR”
от едната
страна и “SEH” от другата.
Zomarist 50 mg/1000 mg филмирани таблетки
Тъмножълта, елипсовидна филмирана
таблетка със скосени ръбове, с
напечатани “NVR” от
едната страна и “FLO” от другата.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Zomarist е показан като допълнение към
диетата и упражненията за подобрение
на гликемичния
контрол при възрастни със захарен
диабет тип 2:
-
при пациенти, при които не е възможно
да се 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 08-01-2024
Public Assessment Report Public Assessment Report Spanish 07-09-2021
Patient Information leaflet Patient Information leaflet Czech 08-01-2024
Public Assessment Report Public Assessment Report Czech 07-09-2021
Patient Information leaflet Patient Information leaflet Danish 08-01-2024
Public Assessment Report Public Assessment Report Danish 07-09-2021
Patient Information leaflet Patient Information leaflet German 08-01-2024
Public Assessment Report Public Assessment Report German 07-09-2021
Patient Information leaflet Patient Information leaflet Estonian 08-01-2024
Public Assessment Report Public Assessment Report Estonian 07-09-2021
Patient Information leaflet Patient Information leaflet Greek 08-01-2024
Public Assessment Report Public Assessment Report Greek 07-09-2021
Patient Information leaflet Patient Information leaflet English 08-01-2024
Public Assessment Report Public Assessment Report English 07-09-2021
Patient Information leaflet Patient Information leaflet French 08-01-2024
Public Assessment Report Public Assessment Report French 07-09-2021
Patient Information leaflet Patient Information leaflet Italian 08-01-2024
Public Assessment Report Public Assessment Report Italian 07-09-2021
Patient Information leaflet Patient Information leaflet Latvian 08-01-2024
Public Assessment Report Public Assessment Report Latvian 07-09-2021
Patient Information leaflet Patient Information leaflet Lithuanian 08-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 08-01-2024
Public Assessment Report Public Assessment Report Lithuanian 07-09-2021
Patient Information leaflet Patient Information leaflet Hungarian 08-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 08-01-2024
Public Assessment Report Public Assessment Report Hungarian 07-09-2021
Patient Information leaflet Patient Information leaflet Maltese 08-01-2024
Public Assessment Report Public Assessment Report Maltese 07-09-2021
Patient Information leaflet Patient Information leaflet Dutch 08-01-2024
Public Assessment Report Public Assessment Report Dutch 07-09-2021
Patient Information leaflet Patient Information leaflet Polish 08-01-2024
Public Assessment Report Public Assessment Report Polish 07-09-2021
Patient Information leaflet Patient Information leaflet Portuguese 08-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 08-01-2024
Public Assessment Report Public Assessment Report Portuguese 07-09-2021
Patient Information leaflet Patient Information leaflet Romanian 08-01-2024
Public Assessment Report Public Assessment Report Romanian 07-09-2021
Patient Information leaflet Patient Information leaflet Slovak 08-01-2024
Public Assessment Report Public Assessment Report Slovak 07-09-2021
Patient Information leaflet Patient Information leaflet Slovenian 08-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 08-01-2024
Public Assessment Report Public Assessment Report Slovenian 07-09-2021
Patient Information leaflet Patient Information leaflet Finnish 08-01-2024
Public Assessment Report Public Assessment Report Finnish 07-09-2021
Patient Information leaflet Patient Information leaflet Swedish 08-01-2024
Public Assessment Report Public Assessment Report Swedish 07-09-2021
Patient Information leaflet Patient Information leaflet Norwegian 08-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 08-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 08-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 08-01-2024
Patient Information leaflet Patient Information leaflet Croatian 08-01-2024
Public Assessment Report Public Assessment Report Croatian 07-09-2021

View documents history